A novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer - Wu, Yuan-Hua; Hong, Chi-Wei; Wang, Yi-Ching; Huang, Wei-Jan; Yeh, Ya-Ling; Wang, Bour-Jr; Wang, Ying-Jan; Chiu, Hui-Wen (Cancer letters, 2017)
Keywords: Acetylation; Acridines - pharmacology; AKT protein; American Type Culture Collection; Androgens; Angiogenesis inhibitors; Animal models; Animals; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antitumor agents; Apoptosis; Apoptosis - drug effects; Atmosphere; Autophagy; Autophagy - drug effects; Breast cancer; Cancer therapies; Carrier Proteins - metabolism; Cell cycle; Cell death; Cell Line, Tumor; Chemotherapy; Chromatin; Cytotoxicity; Deoxyribonucleic acid; DNA; DNA Damage; DNA End-Joining Repair - drug effects; DNA repair; DNA-Activated Protein Kinase - metabolism; DNA-Binding Proteins - metabolism; Dose-Response Relationship, Drug; Drug Synergism; Drugs; Enzymes; Etoposide - pharmacology; Female; Gene expression; Hematology, Oncology and Palliative Medicine; Histone Deacetylase Inhibitors - pharmacology; Humans; Hydroxamic Acids - pharmacology; Inflammation; Kinases; Lymphoma; Medical prognosis; Membrane vesicles; Metastases; Mice; Mice, Inbred BALB C; Mice, Nude; Nuclear Proteins - metabolism; Organelles; Proteasome Endopeptidase Complex - metabolism; Proteasomes; Proteins; Proteolysis; Time Factors; Topoisomerase II Inhibitors - pharmacology; Transmissible spongiform encephalopathy; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - enzymology; Triple Negative Breast Neoplasms - genetics; Triple Negative Breast Neoplasms - pathology; Triple-negative breast cancer; Tumor cells; Tumors; Ubiquitin-protein ligase; Ubiquitin-Protein Ligases - metabolism; Ubiquitination; Ubiquitin–proteasome system; DNA repair; DNA damage; Ubiquitin–proteasome system; Triple-negative breast cancer; ubiquitin-proteasome system; triple-negative breast cancer